Research Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

In Silico Homology Modeling of Presenilin 2- Therapeutic Target for Alzheimer’s Disease


Affiliations
1 Department of Bio-Engineering, School of Engineering, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai-600117, Tamilnadu, India
     

   Subscribe/Renew Journal


Alzheimer’s disease is a neurodegenerative disorder which is caused by several mutations in causative proteins like Amyloid Precursor Protein (APP), Presenilin1 (PSEN1), and Presenilin2 (PSEN2). Mutations in presenilin 2 lead to the overproduction of amyloid beta peptide which gets accumulated in the brain and causes neuron death. This result in Early Onset Alzheimer’s disease (EOAD) and there are around 17 mutations in presenilin 2 results in this disease condition. There are 3 isoforms of PSEN2 which are normally found in the cells. Three dimensional structure of presenilin 2 has not been determined; hence, in this study the structure of presenilin 2 was predicted using homology modeling. The 3dimensional structures are modeled using Modeller9.20, Swiss Model and Geno3D. The structures are validated using PROCHECK. The structure of Swiss Model was found to be more reliable with fewer amino acids in the disallowed region, followed by Modeller9.0 and Geno3D. These structures will be fundamental in determining the crystal structure of presenilin 2 and for drug discovery.

Keywords

Homology Modeling, Presenilin 2, Alzheimer’s Disease, Modeller9.20, Swiss Model, Geno3D.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Dickson DW. Neuropathological diagnosis of Alzheimer’s disease: a perspective from longitudinal clinicopathological studies. Neurobiology of aging. 1997 Jul 1, 18(4): S21-6.

  • Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer’s disease. In Ageing and dementia 1998 (pp. 127-140). Springer, Vienna.

  • Żekanowski C, Styczyńska M, Pepłońska B, Gabryelewicz T, Religa D, Ilkowski J, Kijanowska-Haładyna B, Kotapka-Minc S, Mikkelsen S, Pfeffer A, Barczak A. Mutations in presenilin 1, presenilin 2 and amyloid precursor protein genes in patients with early-onset Alzheimer's disease in Poland. Experimental neurology. 2003 Dec 1, 184(2): 991-6.

  • Youn YC, Bagyinszky E, Kim H, Choi BO, An SS, Kim S. Probable novel PSEN2 Val214Leu mutation in Alzheimer’s disease supported by structural prediction. BMC neurology. 2014 Dec, 14(1):105.

  • Hardy J. A hundred years of Alzheimer's disease research. Neuron. 2006 Oct 5;52(1):3-13.

  • Eswar N, Webb B, Marti‐Renom MA, Madhusudhan MS, Eramian D, Shen MY, Pieper U, Sali A. Comparative protein structure modeling using Modeller. Current protocols in bioinformatics. 2006 Sep 1, 15(1): 5-6.

  • Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics. 2006 Jan 15, 22(2):195-201.

  • Rademakers R, Cruts M, Van Broeckhoven C. Genetics of early-onset Alzheimer dementia. The Scientific World Journal. 2003, 3:497-519.

  • Annaert WG, Levesque L, Craessaerts K, Dierinck I, Snellings G, Westaway D, George-Hyslop PS, Cordell B, Fraser P, De Strooper B. Presenilin 1 controls γ-secretase processing of amyloid precursor protein in pre-Golgi compartments of hippocampal neurons. The Journal of cell biology. 1999 Oct 18, 147(2):277-94.

  • De Strooper B, Iwatsubo T, Wolfe MS. Presenilins and γ-secretase: structure, function, and role in Alzheimer disease. Cold Spring Harbor perspectives in medicine. 2012 Jan 1, 2(1):a006304.

  • Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nature medicine. 1997 Jan;3(1):67.

  • Walker ES, Martinez M, Brunkan AL, Goate A. Presenilin 2 familial Alzheimer's disease mutations result in partial loss of function and dramatic changes in Aβ 42/40 ratios. Journal of neurochemistry. 2005 Jan;92(2):294-301.

  • Zatti G, Burgo A, Giacomello M, Barbiero L, Ghidoni R, Sinigaglia G, Florean C, Bagnoli S, Binetti G, Sorbi S, Pizzo P. Presenilin mutations linked to familial Alzheimer's disease reduce endoplasmic reticulum and Golgi apparatus calcium levels. Cell calcium. 2006 Jun 1, 39(6): 539-50.

  • Zatti G, Ghidoni R, Barbiero L, Binetti G, Pozzan T, Fasolato C, Pizzo P. The presenilin 2 M239I mutation associated with familial Alzheimer's disease reduces Ca2+ release from intracellular stores. Neurobiology of disease. 2004 Mar, 15(2):269-78.

  • Bai YF, Tian J, Quan WX, Maeda K. Association of Mutations of Presenilin-2 Gene and Sporadic Alzheimer's Disease. Journal of China Medical University. 2011 Apr, 40(4): 357-9.

  • Martí-Renom MA, Stuart AC, Fiser A, Sánchez R, Melo F, Šali A. Comparative protein structure modeling of genes and genomes. Annual review of biophysics and biomolecular structure. 2000 Jun, 29(1): 291-325.

  • Šali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. Journal of molecular biology. 1993 Dec 5, 234(3):779-815.

  • Gill SC, Von Hippel PH. Calculation of protein extinction coefficients from amino acid sequence data. Analytical biochemistry. 1989 Nov 1, 182(2): 319-26.

  • Guruprasad K, Reddy BB, Pandit MW. Correlation between stability of a protein and its dipeptide composition: a novel approach for predicting in vivo stability of a protein from its primary sequence. Protein Engineering, Design and Selection. 1990 Dec 1, 4(2): 155-61.

  • Gasteiger E, Hoogland C, Gattiker A, Wilkins MR, Appel RD, Bairoch A. Protein identification and analysis tools on the ExPASy server. In The proteomics protocols handbook 2005 (pp. 571-607). Humana press.

  • Geourjon C, Deleage G. SOPMA: significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments. Bioinformatics. 1995 Dec 1, 11(6): 681-4.

  • Combet C, Jambon M, Deleage G, Geourjon C. Geno3D: automatic comparative molecular modelling of protein. Bioinformatics. 2002 Jan 1, 18(1): 213-4.

  • Ramachandran GT, Sasisekharan V. Conformation of polypeptides and proteins. In Advances in protein chemistry 1968 Jan 1 (Vol. 23, pp. 283-437). Academic Press.

  • Vriend G. WHAT IF: a molecular modeling and drug design program. Journal of molecular graphics. 1990 Mar 1;8(1):52-6.

  • Guex N, Peitsch MC. SWISS‐MODEL and the Swiss‐Pdb Viewer: an environment for comparative protein modeling. electrophoresis. 1997;18(15):2714-23.


Abstract Views: 389

PDF Views: 0




  • In Silico Homology Modeling of Presenilin 2- Therapeutic Target for Alzheimer’s Disease

Abstract Views: 389  |  PDF Views: 0

Authors

Sowmya Hari
Department of Bio-Engineering, School of Engineering, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai-600117, Tamilnadu, India
S. Akilashree
Department of Bio-Engineering, School of Engineering, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai-600117, Tamilnadu, India

Abstract


Alzheimer’s disease is a neurodegenerative disorder which is caused by several mutations in causative proteins like Amyloid Precursor Protein (APP), Presenilin1 (PSEN1), and Presenilin2 (PSEN2). Mutations in presenilin 2 lead to the overproduction of amyloid beta peptide which gets accumulated in the brain and causes neuron death. This result in Early Onset Alzheimer’s disease (EOAD) and there are around 17 mutations in presenilin 2 results in this disease condition. There are 3 isoforms of PSEN2 which are normally found in the cells. Three dimensional structure of presenilin 2 has not been determined; hence, in this study the structure of presenilin 2 was predicted using homology modeling. The 3dimensional structures are modeled using Modeller9.20, Swiss Model and Geno3D. The structures are validated using PROCHECK. The structure of Swiss Model was found to be more reliable with fewer amino acids in the disallowed region, followed by Modeller9.0 and Geno3D. These structures will be fundamental in determining the crystal structure of presenilin 2 and for drug discovery.

Keywords


Homology Modeling, Presenilin 2, Alzheimer’s Disease, Modeller9.20, Swiss Model, Geno3D.

References